Al Sandrock predicts Alzheimer's treatment will shift from managing symptoms to prevention. Like cholesterol, amyloid buildup will be monitored via routine blood tests, allowing for treatment to be administered early to prevent irreversible neuron loss before cognitive impairment begins.

The focus in Alzheimer's treatment is moving from merely slowing decline in late-stage patients to early prevention. By using anti-amyloid drugs to clear plaques before significant brain damage occurs, it may be possible to prevent the disease's onset entirely.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

Diverging from typical approaches that focus on damaged neurons, Neuvivo's drug addresses ALS as an immune system disorder. By supplying a molecule the immune system is missing, it helps regulate the system, allowing the body to recover from the attacks that cause neurodegeneration.

Coya's therapeutic approach is not limited to ALS. The company views the underlying mechanism—dysfunctional regulatory T-cells driving neuroinflammation—as a common pathway in other conditions like frontotemporal dementia, Alzheimer's, and Parkinson's. This positions their drug as a platform technology, creating a broader pipeline and de-risking the company from reliance on a single indication.

While T-regs are most commonly associated with autoimmune conditions, Coya focuses on neurodegeneration. This strategy is based on their founder's research showing T-reg dysfunction is a major driver of diseases like ALS and FTD, applying a known biological mechanism to a novel, high-unmet-need therapeutic area.

Shifting focus from amyloid plaque, Dr. Francisco Gonzalez Lima's research suggests viewing Alzheimer's as a vascular disease rooted in mitochondrial dysfunction. This perspective opens new treatment avenues like low-dose methylene blue and photobiomodulation to improve mitochondrial function.

The T-cell delivery system is versatile. It can carry T-cell engagers for cancer, but also antibodies for Alzheimer's or oligonucleotides. By using different T-cell types (like regulatory T-cells), it can also be used to reduce inflammation, expanding its applicability beyond oncology.

Voyager's CEO explains that amyloid and tau are not independent culprits in Alzheimer's. Tau clumps naturally with age in a small brain region. Amyloid accumulation then acts as a trigger, causing this "tau fire" to spread catastrophically, suggesting treatments may need to address both.